Skip to main content


For further information on COVID-19 please click here.

UHCW are working with colleagues in the UK and all around the world in the fight against COVID-19. Patients who have COVID may be invited to take part in these studies if they meet the inclusion criteria.

We are also taking part in a number of studies looking at the impact of COVID on patients and services at the Trust, which we may ask patients to participate in.

Patients are under no obligation to take part, and their standard care will not be affected if they decide not to take part.

Some of the studies we are currently conducting are below.

COVID-19 Follow-up Study

UHCW Multidisciplinary Post-Covid-19 Follow-up Study

This study aims to prospectively capture clinical/laboratory data from the UHCW post-Covid-19 clinical pathway in order to characterise the residual problems and relevant healthcare needs of patients that recovered from COVID-19.

Find out more here


Immunogenicity of vaccine VLA2001 compared to AZD1222 (Oxford-AstraZeneca vaccine). The COV-COMPARE trial.

Valneva’s Phase three clinical trial will test a new vaccine candidate against Covid-19. This study will investigate the level of antibodies against Covid-19 induced by the vaccine candidate VLA2001 and whether it is safe to use. Volunteers will receive two doses of the vaccine four weeks apart and are required to attend up to eight follow-up visits over 13 months. Inconvenience payments will be available.

Find out more here.


REHABILITATIon exercise and psychological support after covid-19 infection

This study aims to find out whether a single online session of exercise advice and support or an 8 week online exercise and support programme is better for helping people recover after being in hospital with Covid-19.

Find out more here.


Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease 19

This trial aims to explore the effectiveness of a new drug taken orally, called IMU-838, in combination with Oseltamivir (Tamiflu) – one of the most widely used flu treatments in the UK – in patients with confirmed or suspected Covid-19.

Find out more here


A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients

The ACCORD platform will test several different drugs to understand how they improve clinical outcomes in patients admitted to hospital with Covid-19. If positive results are seen, these drugs will be included in large-scale Covid-19 trials such as the RECOVERY trial.

Find out more here


Genetics Of Mortality In Critical Care

GenOMICC is a research study that looks at the DNA of people with severe infections and injuries. Our genes (DNA) can determine how much critical illness affects us. We want to find the genes that cause some people to be more sick. If we do, we may be able to develop better treatments for patients in the future.

Find out more here


A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia

This is an international adaptive platform trial in community acquired pneumonia, that was specifically designed to be employed in a pandemic to evaluate multiple interventions simultaneously in critically ill patients.

Find out more here


Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia

This is a clinical trial looking at the effects of a medication called canakinumab on patients with Covid-19 pneumonia (an infection in one or both lungs). Patients who take part will be randomised to receive either canakinumab or placebo.

Find out more here


A Randomised, Double-blind, Placebo Controlled Study of Eicosapentaenoic Acid (EPA-FFA) Gastro-resistant Capsules to Treat Hospitalised Subjects With Confirmed SARS-CoV-2

This is a clinical trial looking at whether Eicosapentaenoic acid (EPA-FFA) gastro-resistant capsules can reduce the inflammation in the lungs of people with Covid-19 infection and also whether it prevents more serious lung problems developing.

Find out more here


Coronavirus infection in primary or secondary immunosuppressed children

This study aims to monitor children and young people who have a condition or are taking medication that affects their immune system and makes them more vulnerable to infections during the coronavirus pandemic. Parents of immunosuppressed children, and the children and teenagers themselves, record their experiences of viral respiratory illnesses including Covid-19 on an online questionnaire.


Clinical Characterisation Protocol for Severe Emerging Infection

The purpose of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) is to prevent illness and deaths from infectious disease outbreaks. This research aims to study Covid-19 to better understand its spread and behaviour. This will be done by collecting and analysing biological samples and data from patients with confirmed cases of the disease across the UK.

Find out more here

Please click here to find out how participant data is used in the ISARIC study.


Pregnancy and Neonatal Outcomes in COVID-19

PAN COVID is a global registry of women with suspected or confirmed Covid-19 infection in pregnancy and their newborn babies.

Find out more here.


Randomised evaluation of COVID-19 therapy

This national clinical trial aims to identify treatments that may be beneficial for people who have been admitted to hospital with suspected or confirmed Covid-19.

Find out more here


Maternal and perinatal outcomes of pandemic influenza or novel coronavirus in pregnancy

This study uses the UK Obstetric Surveillance System (UKOSS) to collect information about pregnant women who are admitted to hospital with confirmed Covid-19 infection, their health and the health of their baby or babies.

Find out more here